Equities research analysts predict that Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) will announce earnings of $0.11 per share for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Catalyst Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.11 and the lowest estimate coming in at $0.10. Catalyst Pharmaceuticals also posted earnings per share of $0.11 during the same quarter last year. The business is expected to report its next quarterly earnings report on Monday, March 21st.
According to Zacks, analysts expect that Catalyst Pharmaceuticals will report full year earnings of $0.39 per share for the current fiscal year, with EPS estimates ranging from $0.38 to $0.41. For the next financial year, analysts expect that the company will report earnings of $0.50 per share, with EPS estimates ranging from $0.44 to $0.61. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings data on Tuesday, November 9th. The biopharmaceutical company reported $0.10 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.10. Catalyst Pharmaceuticals had a return on equity of 25.85% and a net margin of 31.16%. The company had revenue of $35.95 million for the quarter, compared to analyst estimates of $34.47 million. During the same period in the previous year, the firm earned $0.11 earnings per share.
Shares of NASDAQ:CPRX opened at $6.24 on Friday. The stock’s 50 day moving average is $6.88 and its 200-day moving average is $6.06. Catalyst Pharmaceuticals has a twelve month low of $3.27 and a twelve month high of $7.58. The firm has a market capitalization of $643.46 million, a price-to-earnings ratio of 16.00 and a beta of 1.28.
In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 3,612 shares of Catalyst Pharmaceuticals stock in a transaction on Tuesday, December 7th. The stock was sold at an average price of $6.99, for a total transaction of $25,247.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 12.80% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in CPRX. LSV Asset Management boosted its stake in shares of Catalyst Pharmaceuticals by 24.0% in the third quarter. LSV Asset Management now owns 5,259,705 shares of the biopharmaceutical company’s stock worth $27,876,000 after acquiring an additional 1,019,389 shares during the period. JPMorgan Chase & Co. raised its position in Catalyst Pharmaceuticals by 142.8% during the second quarter. JPMorgan Chase & Co. now owns 1,331,083 shares of the biopharmaceutical company’s stock valued at $7,654,000 after purchasing an additional 782,870 shares during the period. Wells Fargo & Company MN grew its stake in shares of Catalyst Pharmaceuticals by 540.1% during the second quarter. Wells Fargo & Company MN now owns 781,091 shares of the biopharmaceutical company’s stock valued at $4,491,000 after buying an additional 659,072 shares during the last quarter. Aviva PLC bought a new position in shares of Catalyst Pharmaceuticals during the third quarter valued at approximately $1,730,000. Finally, Dimensional Fund Advisors LP grew its stake in Catalyst Pharmaceuticals by 20.1% in the third quarter. Dimensional Fund Advisors LP now owns 1,753,974 shares of the biopharmaceutical company’s stock worth $9,294,000 after purchasing an additional 293,033 shares in the last quarter. 63.20% of the stock is owned by institutional investors and hedge funds.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.